Cancer patients, especially those undergoing chemotherapy or hematopoietic stem cell transplantation (HSCT), are at increased risk of infections due to their weakened immune systems. Prophylactic use of antimicrobials can significantly reduce the incidence of severe infections, which can otherwise lead to treatment delays, increased healthcare costs, and higher mortality.
